TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Mobile App for Prenatal Care to Reduce Visits and Improve Satisfaction Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible participants will be women who are between 18 than 40-years-old, who are visiting the OB for a first-trimester verification of pregnancy visit, new OB visit or follow-up OB visit, who are low-risk per treating OB, who regularly use a smart-phone, who can understand and consent to English-written consent form.~* Eligible clinicians will be attending obstetric physicians who refer the patient to the research assistant for informed consent and full eligibility assessment.~Exclusion Criteria:~* High-risk obstetrical condition\*~* Intends midwifery care~* Intends to terminate~* Not Local resident~* Non--English speaker

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Babyscripts Prenatal App (Type: ACTIVE_COMPARATOR): For patients allocated to the experimental group, they will be assisted in downloading the BRx app to their smartphone and set up the connected weight scale and blood pressure cuff. At time of enrollment, research assistant will also collect baseline demographic and clinical data. For patients allocated to this study arm, the clinician will be informed and therefore, will be receiving regular app-based education while the clinician will be receiving regular blood pressure and weight measurements. Following that communication, it will be the physicians' judgement to reduce in-person visits from usual care.
- Placebo (Type: PLACEBO_COMPARATOR): For patients cared for by clinicians allocated to the control (usual care) arm, the clinician will discuss the management options and scheduling procedures with the patient in that clinician's usual fashion. The patient will not be given access to the BRx app but will consent to the study data collection and survey administration. All potential study subjects will receive standard medical care per DoD/VA Clinical Practice Guidelines for Management of the uncomplicated pregnancy (REF) and local preference by board-certified OB/GYN physicians.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic heart failure with known or recently diagnosed intolerance of treatment with first-line medication for heart failure~* May or may not be receiving an alternative and/or additional drug treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Losartan 50 mg (Type: EXPERIMENTAL): 50-mg losartan tablet administered daily with 1 tablet of 100-mg losartan placebo beginning Week 1 and continuing to end of study (up to 4 years)
- Losartan 150 mg (Type: EXPERIMENTAL): Titrated losartan administration up to daily 150-mg losartan: Week 1, daily 50-mg losartan tablet coadministered with 100-mg losartan placebo; Week 2, daily 50-mg losartan placebo coadministered with 100-mg losartan; Week 3 to end of study (up to 4 years), daily 50-mg losartan tablet coadministered with 100-mg losartan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject completed the week 12 visit in one of the Phase 2, ASP015K Rheumatoid Arthritis studies within the previous 14 days.~* Male and Female subjects must be willing to comply with contraception requirements as well as restrictions regarding egg and sperm donation~Exclusion Criteria:~* Subject has any condition considered by the Principal Investigator or Medical Monitor to preclude adequate evaluation of drug safety~* Subject is scheduled to receive any investigational drug other than ASP015K during the course of the study~* Subject is scheduled to receive a prohibited medication~* Subject has a planned major surgery~* Subject discontinued study drug due to meeting study drug discontinuation criteria prior to completion of the Week 12 visit in the preceding study or fulfills study drug discontinuation criteria at the final study visit of the preceding study~* Subject has out of range laboratory values within 14 days of the Day 1 study dosing~* Absolute lymphocyte count (ALC) \< 500/mm3~* Creatine Phosphokinase (CPK) \> 1.5 x upper limit of normal unless the level has been stable for at least 2 consecutive blood draws (at least 7 days apart), and subject does not have symptoms of muscle aching, weakness, or severe unusual muscle cramps

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ASP015K (Type: EXPERIMENTAL): Experimental

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with mild and moderate hypertension defined by a MSSBP ≥ 140 mmHG and \< 180 mmHG at Visits 1 and 2 for treated and untreated patients~* Chronic hemodialysis for at least 6 months prior to Visit 1 as substitution therapy.~* If treated with epoetin: patients with a stable hematocrit ≤ 40% (± 5%).~Exclusion Criteria:~* Inability to discontinue angiotensin II receptor blockers (ARBs) safely for a period of 1 week, as required by the protocol.~* Treatment with more than 3 different compounds for the treatment of hypertension at Visit 1.~* Atrial fibrillation~Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Received liver transplant for treatment of hATTR amyloidosis ≥12 months before study start~* Has increase in polyneuropathy disability (PND) score after liver transplant~* Has received stable immunosuppressive regimen with ≤10 mg/day of prednisone for at least 3 months before study start~* Has Karnofsky Performance Status (KPS) of ≥70%~* Has vitamin A level greater than or equal to lower limit of normal~Exclusion Criteria:~* Has previously received inotersen or patisiran~* Has clinically significant liver function test abnormalities~* Has known portal hypertension with ascites~* Has estimated glomerular filtration rate (eGFR) ≤30 mL/min/1.73 m\^2~* Has known leptomeningeal amyloidosis~* Has infection with hepatitis B, hepatitis C or human immunodeficiency virus (HIV)~* Has New York Heart Association heart failure classification of \>2~* Is wheelchair bound or bedridden~* Has received organ transplants other than liver transplant~* Will be using another tetramer stabilizer during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patisiran (Type: EXPERIMENTAL): Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Completed study drug treatment in parent study (VX18-445-109); or had study drug interruption(s) in parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study~Key Exclusion Criteria:~* History of study drug intolerance in parent study~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ELX/TEZ/IVA (Type: EXPERIMENTAL): Part A: Participants received elexacaftor (ELX) 200 milligram (mg) once daily (qd)/tezacaftor (TEZ)100 mg qd/ivacaftor (IVA)150 mg every 12 hours (q12h) in the treatment period for 48 weeks.~Part B: Participants received ELX 200 mg qd/TEZ 100 mg qd/IVA 150 mg q12h in the treatment period up to 86 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Objective and subjective evidence of presbyopia.~Exclusion Criteria:~* Corneal abnormalities (including keratoconus, corneal scar, Fuchs' endothelial dystrophy, guttata, or edema) in either eye that are likely to interfere with visual acuity.~* Narrow iridocorneal angles (Shaffer grade \<=2 or lower on gonioscopy examination), history of angle-closure glaucoma, or previous iridotomy.~* Diagnosis of any type of glaucoma or ocular hypertension.~* History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery, radial keratotomy, or any intraocular surgery.~* Use of temporary or permanent punctal plugs or history of punctal cautery in one or both eyes.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Vehicle (Type: PLACEBO_COMPARATOR): Participants received vehicle, one drop bilaterally (in each eye), twice daily (BID), with a gap of 6 hours between both doses, for up to 14 days.
- AGN-190584 (Type: EXPERIMENTAL): AGN-190584 ophthalmic solution, one drop bilaterally (in each eye), BID, with a gap of 6 hours between both doses, for up to 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have suspicion of DCIS or early invasive breast cancer on mammography.~* Patients must have histologically confirmed diagnosis of DCIS or early invasive breast cancer on core biopsy for final registration.~* Patients must be over 18 years of age~* Patients must be postmenopausal as defined by one of the following criteria:~  1. Prior bilateral oophorectomy OR~ 2. \> 12 months since LMP with no prior hysterectomy OR~ 3. a \& b not applicable AND age \>=50~* Patients must be positive for either ER or PR or both~* Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.~Exclusion Criteria:~* Patients must not have diagnosis of osteoporosis (T-score -2.5 according to the WHO)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anastrozole (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Iguratimod in Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of RA~* Subjects who have active RA at the time of screening~* Subjects who haven't used any antirheumatic drugs or have used antirheumatic drugs for more than 3 months at the time of screening~* Written informed consent~Exclusion Criteria:~* Subjects with serious cardiovascular, renal, hematologic or endocrine diseases~* Pregnant or lactating women~* ALT\>1.5×ULN, AST\>1.5×ULN, Cr\>135umol/L~* WBC\<4×109/L，HGB\<85g/L，PLT\<100×109/L~* Subjects with uncontrolled infection~* Patients with active gastrointestinal diseases (such as gastric ulcer, etc.)~* Allergic to any of the study drugs~* History of alcoholism~* Subjects receiving live vaccines within 3 months prior to study entry~* Subjects participating in other clinical study within 3 months prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iguratimod (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Topiramate in the Treatment of Alcohol Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have a current diagnosis of alcohol dependence~* drink an average of 28 or more standard drinking units/week for women or 35 or more standard drinking units/week for men~* have a desire to stop drinking completely or to reduce alcohol consumption with the possible long-term goal of abstinence~* have a body mass index of 18 or more~* sexually active women capable of having children must be using an acceptable method of birth control~* must be in generally good health.~Exclusion Criteria:~* No current or recent (within 6 months) diagnosis of other substance abuse or dependence~* no inpatient or outpatient counseling for alcohol dependence other than Alcoholics Anonymous within 4 weeks~* not more than 4 past failed inpatient treatments attempts for alcohol dependence~* no other psychiatric disorder that requires treatment with medication or therapy~* no current probation or parole requirement or legally mandated requirement to participate in an alcohol treatment program.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients \>=18 years of age;~* chronic renal anemia;~* on dialysis therapy for at least 12 weeks before screening;~* receiving darbepoetin alfa iv for at least 8 weeks before screening.~Exclusion Criteria:~* women who are pregnant, breastfeeding or using unreliable birth control methods;~* administration of another investigational drug within 4 weeks before screening, or during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RO0503821 (1x/2 Weeks) (Type: EXPERIMENTAL): Eligible participants will be administered with RO0503821 (\[methoxy polyethylene glycol-epoetin beta\] {Mircera}) intravenously (IV), every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram \[µg\]) was based on the dose of darbepoetin alfa at the time of randomization (\< 40, 40 to 80, or \> 80 µg per week, respectively).
- Darbepoetin (1x/1-2 Weeks) (Type: ACTIVE_COMPARATOR): Eligible participants will be administered with darbepoetin alfa IV, every week or every 2 weeks during Weeks 1 through 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sexual Function and Wellbeing in Females With Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Females diagnosed with rectal cancer stadium I-III, planned surgery with or without preoperative radiotherapy.~Exclusion Criteria:~* Rectal cancer stadium IV~* Previous radiotherapy to the pelvic region~* Inability to provide informed consent.~* Life expectancy less than 2 years.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Preoperative radiotherapy (Type: None): Women with rectal cancer treated with preoperative radiotherapy (RT) and surgery.
- No preoperative radiotherapy (Type: None): Women with rectal cancer treated with surgery alone (no RT).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Differential Effect of High (200μg/kg/Min) Adenosine Dose on Fractional Flow Reserve in Patients Presenting Variation of FFR ≥0.05 During the Usual Dose of Adenosine Infusion (140μg/kg/Min).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18-80 years~2. Patients with at least 1 ≥50% stenosis in a coronary vessel, subjected to FFR assessment, who exhibit variation in Pd / Pa ratio ≥ 0.05 (e.g. difference of max Pd/Pa minus min Pd/Pa) during steady state hyperaemia (determined by visual assessment).~3. Written informed consent~Exclusion Criteria:~1. Left main disease (angiographically\> 50%)~2. Cardiogenic shock / hemodynamic instability~3. Previous CABG~4. Increased risk of bradycardia on investigator clinical judgment~5. Severe chronic obstructive pulmonary disease~6. Coronary vessels with tortuosity or extremely calcified~7. Severe left ventricular hypertrophy or severe valvular disease~8. STEMI or non-STEMI within the past five days~9. Previous myocardial infarction in the distribution of the target vessel for the FFR~10. Acute decompensated heart failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Adenosine intravenous infusion at 200μg/Kg/min (Type: EXPERIMENTAL): Fractional flow reserve assessment under Adenosine intravenous infusion at 200μg/Kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neurological symptoms and/or findings consistent with neuroborreliosis and at least one of the following fulfilled:~  * Intrathecal production of borrelia antibodies;~ * White cell count in cerebrospinal fluid (CSF) \> 5/mm3;~ * Significant rise in borrelia antibodies in two serum samples collected from a patient with at least 3 weeks interval;~ * Verified acrodermatitis chronica atrophicans.~Exclusion Criteria:~* Allergy to the contents in the medication, or earlier type I reaction to penicillin.~* Treatment with cephalosporins, penicillin or tetracyclins during the last 14 days~* Pregnancy or breastfeeding~* Age \< 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Doxycycline
- 2 (Type: ACTIVE_COMPARATOR): cephtriaxone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete